tradingkey.logo
tradingkey.logo
Buscar

Renovaro Inc

RENB
Añadir a la lista de seguimiento
1.420USD
0.0000.00%
Horarios del mercado ETCotizaciones retrasadas 15 min
14.83MCap. mercado
PérdidaP/E TTM

Más Datos de Renovaro Inc Compañía

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Información de Renovaro Inc

Símbolo de cotizaciónRENB
Nombre de la empresaLunai Bioworks Inc
Fecha de salida a bolsaNov 18, 2014
Director ejecutivoWeinstein (David)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 18
Dirección2080 Century Park East, Suite 906
CiudadLOS ANGELES
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal90067
Teléfono14539179840
Sitio Web
Símbolo de cotizaciónRENB
Fecha de salida a bolsaNov 18, 2014
Director ejecutivoWeinstein (David)

Ejecutivos de Renovaro Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Renovaro Inc?

Los cinco principales accionistas de Renovaro Inc son: Mr. Douglas W. Calder

¿Cuántas instituciones poseen acciones de Renovaro Inc (RENB)?

A fecha de 2026Q1, 139 instituciones poseen acciones de Renovaro Inc, con un valor de mercado combinado de aproximadamente 1.10M, lo que representa el 3.04% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -513101.00.